NADclinic Group and the Geneva College of Longevity Science (GCLS) have announced a strategic educational collaboration intended to give clinicians across the NADclinic network greater access to structured postgraduate and professional education in longevity, preventive longevity medicine and performance medicine.
The partnership is described as focusing on responsible education, clinical context, regulatory awareness and measurable patient outcomes, the company claims.
A central element is access to GCLS programmes such as the Postgraduate Diploma in Peptide Therapeutics; according to published GCLS course information, the diploma spans 28 modules, about 80 contact hours, an expected 12-week duration, carries 10 ECTS credits and concludes with a capstone case study.
The collaboration will also support development of PHI Peptides, NADclinic Group’s clinician-led longevity and performance medicine platform, which the company says is built around education, clinical guidance and responsible access.
Planned activities include education pathways for NADclinic-affiliated clinicians, facilitating access to GCLS postgraduate and continuing professional education for licensed healthcare professionals, joint webinars and masterclasses, emphasis on evidence-based practice and regulatory awareness, and clear referral pathways subject to agreed commercial terms.
The partners say the aim is a more mature, education-led approach to clinical adoption internationally.
